Compound useful for the treatment of degenerative and inflammatory diseases
US-9309244-B2 · Apr 12, 2016 · US
Compound useful for the treatment of degenerative and inflammatory diseases
US9707237B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9707237-B2 |
| Application number | US-201615095317-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 11, 2016 |
| Priority date | Jun 26, 2009 |
| Publication date | Jul 18, 2017 |
| Grant date | Jul 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A novel compound able to inhibit JAK is disclosed, that comprises a compound according to Formula I: or a pharmaceutically acceptable salt thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutically acceptable salt of a compound according to Formula I: wherein said pharmaceutically acceptable salt is a maleic acid salt. 2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a pharmaceutically acceptable salt of a compound according claim 1 . 3. The pharmaceutical composition according to claim 2 comprising a further therapeutic agent. 4. A method for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders, comprising administering an amount of a pharmaceutically acceptable salt of claim 1 , sufficient to effect said treatment. 5. The method according to claim 4 , wherein the said pharmaceutically acceptable salt is administered in combination with a further therapeutic agent. 6. The pharmaceutical composition according to claim 2 , wherein the further therapeutic agent is an agent for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders. 7. A method for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders, comprising administering an amount of a pharmaceutical composition of claim 2 , sufficient to effect said treatment. 8. A method for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders, comprising administering an amount of a pharmaceutical composition of claim 3 , sufficient to effect said treatment. 9. The method according to claim 7 , wherein the pharmaceutical composition is administered in combination with a further therapeutic agent. 10. The method according to claim 8 , wherein the pharmaceutical composition is administered in combination with a further therapeutic agent. 11. The method according to claim 5 , wherein the further therapeutic agent is an agent for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders. 12. The method according to claim 9 , wherein the further therapeutic agent is an agent for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders. 13. The method according to claim 10 , wherein the further therapeutic agent is an agent for the treatment of rheumatoid arthritis, psoriasis, transplant rejection, or inflammatory bowel disorders.
Assignees
Inventors
Classifications
Drugs for immunological or allergic disorders · CPC title
Immunomodulators · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9707237B2 cover?
- A novel compound able to inhibit JAK is disclosed, that comprises a compound according to Formula I: or a pharmaceutically acceptable salt thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, aut…
- Who is the assignee on this patent?
- Menet Christel Jeanne Marie, Smits Koen Kurt, Galapagos Nv
- What technology area does this patent fall under?
- Primary CPC classification A61K31/541. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).